{
    "nctId": "NCT00718952",
    "title": "Multi-centre, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Treatment of Pulmonary Arterial Hypertension With Vardenafil in China",
    "symPyJSON": {
        "type": "and",
        "operands": [
            {
                "type": "and",
                "operands": [
                    {
                        "type": "variable",
                        "value": "Subjects aged 12-65"
                    },
                    {
                        "type": "variable",
                        "value": "Confirmed idiopathic pulmonary hypertension"
                    },
                    {
                        "type": "variable",
                        "value": "confirmed connective tissue disease associated pulmonary hypertension"
                    },
                    {
                        "type": "variable",
                        "value": "confirmed congenital heart disease (with Eisenmenger syndrome) associated pulmonary hypertension"
                    },
                    {
                        "type": "variable",
                        "value": "Baseline 6-minutes walking distance 150m-550m"
                    },
                    {
                        "type": "variable",
                        "value": "WHO pulmonary hypertension function II-III with non-responder to calcium channel blockers"
                    },
                    {
                        "type": "variable",
                        "value": "Documented written informed consent"
                    },
                    {
                        "type": "variable",
                        "value": "Must have minimum age of 12 Years"
                    },
                    {
                        "type": "variable",
                        "value": "Must have maximum age of 65 Years"
                    }
                ]
            },
            {
                "type": "not",
                "operands": [
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "The other types of pulmonary hypertension"
                            },
                            {
                                "type": "variable",
                                "value": "Subjects who refuse to subscribe written informed consents or can't cooperate with the trial well"
                            },
                            {
                                "type": "and",
                                "operands": [
                                    {
                                        "type": "variable",
                                        "value": "Subjects with serious acute or chronic disease involved liver"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "serious acute or chronic disease involved kidney"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "serious acute or chronic disease involved brain"
                                    },
                                    {
                                        "type": "variable",
                                        "value": "have to use potent CYP3A4-inhibitor or nitrate to treat the underlying diseases"
                                    }
                                ]
                            },
                            {
                                "type": "variable",
                                "value": "Subjects who are currently treated with sildenafil for PAH"
                            },
                            {
                                "type": "variable",
                                "value": "Subjects currently taking sildenafil or tadalafil"
                            },
                            {
                                "type": "variable",
                                "value": "Other contraindications in package insert"
                            }
                        ]
                    }
                ]
            }
        ]
    },
    "symPyExpression": "And(Symbol('Baseline 6-minutes walking distance 150m-550m'), Symbol('Confirmed idiopathic pulmonary hypertension'), Symbol('Documented written informed consent'), Symbol('Must have maximum age of 65 Years'), Symbol('Must have minimum age of 12 Years'), Symbol('Subjects aged 12-65'), Symbol('WHO pulmonary hypertension function II-III with non-responder to calcium channel blockers'), Symbol('confirmed congenital heart disease (with Eisenmenger syndrome) associated pulmonary hypertension'), Symbol('confirmed connective tissue disease associated pulmonary hypertension'), Not(Or(Symbol('Other contraindications in package insert'), Symbol('Subjects currently taking sildenafil or tadalafil'), Symbol('Subjects who are currently treated with sildenafil for PAH'), Symbol(\"Subjects who refuse to subscribe written informed consents or can't cooperate with the trial well\"), Symbol('The other types of pulmonary hypertension'), And(Symbol('Subjects with serious acute or chronic disease involved liver'), Symbol('have to use potent CYP3A4-inhibitor or nitrate to treat the underlying diseases'), Symbol('serious acute or chronic disease involved brain'), Symbol('serious acute or chronic disease involved kidney')))))"
}